Idelvion
Biological
CSL Behring
Total Payments
$2.3M
Transactions
1,755
Doctors
646
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $25,536 | 120 | 97 |
| 2023 | $31,122 | 186 | 150 |
| 2022 | $50,947 | 291 | 220 |
| 2021 | $183,798 | 275 | 144 |
| 2020 | $790,816 | 266 | 112 |
| 2019 | $544,445 | 287 | 143 |
| 2018 | $430,338 | 223 | 82 |
| 2017 | $210,331 | 107 | 41 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 128 | 67.9% |
| Honoraria | $465,456 | 145 | 20.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,652 | 79 | 4.3% |
| Travel and Lodging | $95,873 | 107 | 4.2% |
| Food and Beverage | $37,735 | 1,226 | 1.7% |
| Consulting Fee | $28,995 | 16 | 1.3% |
| Education | $2,075 | 54 | 0.1% |
Payments by Type
Research
$1.5M
128 transactions
General
$727,786
1,627 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B | CSL Behring | $750,864 | 0 |
| A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin rIX-FP in Patients With Hemophilia B | CSL Behring | $653,268 | 0 |
| A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B | CSL Behring | $117,596 | 0 |
| Evaluating the ability of the CDC heat inactivation protocol to inactivate modified hemophilia treatment products | CSL Behring | $17,820 | 0 |
Top Doctors Receiving Payments for Idelvion — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology | Los Angeles, CA | $8,314 | 11 |
| , MD, PHD | Pediatric Hematology-Oncology | Portland, OR | $8,253 | 7 |
| , MD, PHD | Medical Oncology | Portland, OR | $8,085 | 6 |
| , MD | Pediatric Hematology-Oncology | Nashville, TN | $8,022 | 6 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $7,766 | 15 |
| , M.D | Pediatrics | Orange, CA | $6,207 | 10 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $6,097 | 3 |
| , MD | Hematology & Oncology | San Diego, CA | $6,000 | 4 |
| , M.D | Pediatrics | New York, NY | $5,829 | 6 |
| , MD | Specialist | Williamsville, NY | $5,662 | 9 |
| , MD | Pediatrics | Aurora, CO | $5,497 | 6 |
| , NP | Pediatrics | San Antonio, TX | $5,375 | 13 |
| , M.D | Pediatric Hematology-Oncology | East Lansing, MI | $5,318 | 4 |
| , MD | Internal Medicine | Gilbert, AZ | $5,124 | 8 |
| Richard Lemons | Pediatric Hematology-Oncology | Salt Lake City, UT | $4,979 | 7 |
| , MD | Student in an Organized Health Care Education/Training Program | Chapel Hill, NC | $4,876 | 6 |
| , MD | Pediatrics | Miami, FL | $4,846 | 6 |
| , MD | Pediatric Hematology-Oncology | Torrance, CA | $4,845 | 7 |
| , M.D | Pediatric Hematology-Oncology | Indianapolis, IN | $3,872 | 4 |
| , MD | Pediatrics | Detroit, MI | $3,567 | 4 |
| , MD | Pediatric Hematology-Oncology | Indianapolis, IN | $3,120 | 1 |
| , M.D | Internal Medicine | Detroit, MI | $3,111 | 4 |
| , NP | Pediatric Hematology-Oncology | Washington, DC | $3,076 | 1 |
| , NP | Nurse Practitioner | Boise, ID | $3,076 | 1 |
| , M.D | Pediatrics | Iowa City, IA | $2,342 | 2 |
Ad
Manufacturing Companies
- CSL Behring $2.3M
Product Information
- Type Biological
- Total Payments $2.3M
- Total Doctors 646
- Transactions 1,755
About Idelvion
Idelvion is a biological associated with $2.3M in payments to 646 healthcare providers, recorded across 1,755 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2024. In 2024, $25,536 was paid across 120 transactions to 97 doctors.
The most common payment nature for Idelvion is "Unspecified" ($1.5M, 67.9% of total).
Idelvion is associated with 4 research studies, including "A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B" ($750,864).